pomalidomide has been researched along with Myelodysplastic Syndromes in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors | Studies |
---|---|
Arbab, A; Cotteret, S; Ghez, D; Marzac, C; Saada, V | 1 |
Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
Krönke, J; Lindner, S | 1 |
Wiernik, PH | 1 |
Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
Lentzsch, S; Pan, B | 1 |
Knight, R | 1 |
Crane, E; List, A | 1 |
Galili, N; Raza, A | 1 |
7 review(s) available for pomalidomide and Myelodysplastic Syndromes
Article | Year |
---|---|
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
2 other study(ies) available for pomalidomide and Myelodysplastic Syndromes
Article | Year |
---|---|
Plasma cell dedifferentiation in refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation; Dexamethasone; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Mutation; Myelodysplastic Syndromes; Paraproteinemias; Plasma Cells; Thalidomide; Treatment Failure; Tumor Suppressor Protein p53 | 2021 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |